Drug Design, Development and Therapy (Jun 2019)

Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril

  • Buda V,
  • Andor M,
  • Baibata DE,
  • Cozlac R,
  • Radu G,
  • Coricovac D,
  • Danciu C,
  • Ledeti I,
  • Cheveresan A,
  • Nica C,
  • Tuduce P,
  • Tomescu MC

Journal volume & issue
Vol. Volume 13
pp. 1915 – 1925

Abstract

Read online

Valentina Buda,1,* Minodora Andor,2,* Dana Emilia Baibata,3,4,* Ramona Cozlac,3,4 Gabriela Radu,2 Dorina Coricovac,5 Corina Danciu,6 Ionut Ledeti,7 Adelina Cheveresan,8 Cristian Nica,9 Paul Tuduce,10 Mirela Cleopatra Tomescu21Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 2Department of Medical Semiotics, Faculty of Medicine, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 3Department of Cardiology VI, Faculty of Medicine, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 4Cardiovascular Diseases Institute, Timisoara, Romania; 5Department of Toxicology, Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 6Department of Pharmacognosy, Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 7Department of Physical Chemistry, Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 8Department of Pharmacology, Faculty of Medicine, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 9Department of Surgery, Faculty of Medicine, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 10Department of Balneophysiotherapy, Rheumatology and Rehabilitation, Faculty of Medicine, Vasile Goldis Western University, Arad, Romania*These authors contributed equally to this work Purpose: Endoglin is a transmembrane glycoprotein which plays an important role in maintaining cardiovascular homeostasis. One of its forms, soluble endoglin (sEng), a molecule with antiangiogenic properties, has been found overexpressed in patients suffering from hypercholesterolemia, diabetes mellitus and hypertension, and is proposed as a marker of endothelial damage. Accordingly, we aimed to quantify the efficacy of various antihypertensive regimens on sEng levels, in hypertensive patients with endothelial dysfunction.Patients and methods: 323 patients were enrolled, and there were 99 patients with normal blood pressure values, 106 hypertensive patients under chronic treatment with different types of antihypertensive molecules (beta blockers, calcium channel blockers, and diuretics) in monotherapy, and 118 hypertensive patients under chronic treatment with perindopril. sEng plasma levels were quantified and were correlated with classical methods of assessing the endothelial damage.Results: Patients under chronic treatment with perindopril had lower sEng plasma levels compared with the other group of hypertensive patients under different regimens of antihypertensive treatment (sEng: 4.73±1.39 versus 5.63±2.33, p<0.01).Conclusion: Decreased sEng plasma levels were found in patients under chronic treatment with perindopril, when compared with other antihypertensive regimens of treatment (beta blockers, calcium channel blockers, and/or diuretics).Keywords: ACE inhibitors, essential arterial hypertension, endothelial dysfunction, antiangiogenic therapy, endoglin

Keywords